Sensus Healthcare, Inc. Stock News

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Investors can contact the law firm at no cost to learn more about recovering their losses

Investors can contact the law firm at no cost to learn more about recovering their losses

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Javier Rampolla - Chief Financial Officer Joseph C. Sardano - Co-Founder, Chairman & CEO Michael J.

Sensus (SRTS) Q2 Revenue Falls 21%

BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the second quarter of 2025 and subsequent wee...

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the second quarter of 2025 on Thursday, August 7, 2025. Management will hold a conference c...